Peginesatide

Information about Peginesatide

Peginesatide (peg” in es’ a tide) is a novel synthetic pegylated dipeptide that mimics the effects of erythropoietin on red cell progenitors, despite having no amino acid homology to the native growth factor.

The drug Peginesatide was withdrawn from the US market

Peginesatide was typically given either subcutaneously or intravenously at 4 week intervals, but was withdrawn from the market in 2013 because of reports of severe hypersensitivity reactions. Epoetin, darbepoetin and peginesatide are collectively referred to as erythropoiesis-stimulating agents (ESA). Dosages and dose regimens (daily, three times weekly, weekly, and every two to four weeks) vary by formulation, indications and initial response.

Side effects of Peginesatide

Common side effects include hypertension (particularly in patients with renal disease), muscle and joint aches, fever, dizziness, headache, depression, cough and injection site reactions. Potentially serious, but rare side effects include hypersensitivity reactions, vascular occlusions, stroke and myocardial infarction.

Hematologic Agents Eculizumab, Emapalumab, Emicizumab, Lanadelumab, Ravulizumab

Hematologic Growth Factors

• Granulocyte colony stimulating factors
  • Filgrastim, Pegfilgrastim

• Granulocyte-Macrophage Colony Stimulating Factors
  • Sargramostim

• Erythropoiesis stimulating agents
  • Epoetin, Darbepoetin, Peginesatide

Thrombopoietin receptor agonists and Thrombopoiesis Stimulators

• • Avatrombopag, Eltrombopag, Fostamatinib, Lusutrombopag, Romiplostim, Oprelvekin (IL-11)

• Dailymed label info on Peginesatide
• FDA Peginesatide